NEW YORK (360Dx) – Roche said today that the US Food and Drug Administration has granted clearance for its Ventana MMR IHC panel, which provides clinicians with "a comprehensive group of immunohistochemistry tests" for patients diagnosed with colorectal cancer.

The tests detect proteins associated with a DNA mismatch repair mechanism, and aid in differentiating between sporadic colorectal cancer and probable Lynch syndrome, a hereditary form of colorectal cancer.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.